Tripair™ developed by Coramaze

Coramaze Technologies is a medical technology company focused on improving health equity in structural heart therapy. They have developed the Tripair™ valve repair system, a minimally invasive solution for treating functional Tricuspid Regurgitation (fTR), a heart valve condition affecting millions. The Tripair™ system simplifies the repair process to the level of a right heart catheterization, making it accessible for interventional cardiologists and expanding treatment options for patients who currently lack effective therapies. Based in Israel and Germany, Coramaze aims to address the significant unmet medical need in tricuspid valve treatments. Their technology is designed to be safe and effective, improving patient quality of life and reducing complications associated with heart failure. The company is supported by experienced leadership and investors, and it targets hospitals and cardiac centers worldwide, focusing on enhancing their structural heart therapy offerings.

• Employees19
• Founded2013
• Annual Revenue$3200000
• Total Funding$12978772